Byetta and Januvia Pancreatic Cancer
Patients with Type 2 diabetes may be prescribed Byetta (exenatide) or Januvia (sitagliptin) to help improve their blood sugar levels in combination with diet and exercise. While both of these popular diabetes drugs work in different ways to achieve their intended results, they share a common link to serious pancreatic problems in certain patients, such as pancreatic cancer.
At Ferrer, Poirot & Wansbrough, we are currently reviewing cases of pancreatic cancer linked to Byetta and Januvia. If you or a loved one were diagnosed with pancreatic cancer after taking either of these Type 2 diabetes drugs, you may be entitled to compensation. Contact our drug injury lawyers 24/7 for a free, no-obligation case review—just dial (800) 210-8503 or complete our free online form to get started now.
Byetta and Januvia May Increase Pancreatic Cancer Risk
The U.S. Food and Drug Administration (FDA) has issued a drug safety communication stating that they intend to evaluate potential links between pancreatic cancer and drugs like Byetta and Januvia.
Prior to this communication, the FDA warned of a link between Byetta and Januvia and potentially fatal cases of pancreatitis, and the agency has cited that both of these drugs may double the risk of acute pancreatitis. While the drug warning labels for Byetta and Januvia contain warnings about pancreatitis, they fail to warn patients of potential pancreatic cancer risks.
Now Investigating Byetta and Januvia Pancreatic Cancer Lawsuits
If you or a loved one took Byetta or Januvia and were diagnosed with pancreatic cancer, contact Ferrer, Poirot & Wansbrough. Our lawyers have more than 35 years of experience fighting for injury victims, and we are currently reviewing Byetta and Januvia cases nationwide. Contact us today for a free, no-obligation case review—call (800) 210-8503 or fill out our free online form to get in touch with a member of our 24/7 team.
Byetta® is a registered trademark of Amylin Pharmaceuticals, Inc. Januvia® is a registered trademark of Merck & Co., Inc.
This law firm is not associated with, sponsored by, or affiliated with the U.S. Food and Drug Administration; Amylin Pharmaceuticals, Inc.; or Merck & Co., Inc.